SCHEMBL823964

SCHEMBL823964

CCS(=O)(=O)c1ccc2cc1CN(C)C/C=C/CCOc1cccc(c1)-c1nc(ncc1C)N2

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 20/20 0.76
FLT3 P36888 20/20 0.76
JAK2 O60674 19/20 0.76
CCNA2 P20248 19/20 0.76
CCNA1 P78396 19/20 0.76
PDPK1 O15530 2/20 0.71
ROCK2 O75116 1/20 0.51
CCNK O75909 1/20 0.51
STK10 O94804 1/20 0.51
PRKD3 O94806 1/20 0.51
ABL1 P00519 1/20 0.51
EGFR P00533 1/20 0.51
PRKCB P05771 1/20 0.51
CDK1 P06493 1/20 0.51
RET P07949 1/20 0.51
CYP2D6 P10635 1/20 0.51
CCNB1 P14635 1/20 0.51
FER P16591 1/20 0.51
PRKCA P17252 1/20 0.51
ERCC2 P18074 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL824012 0.86 JAK2 (1.00) CDK2FLT3JAK2CCNA2CCNA1
SCHEMBL824026 0.86 JAK2 (0.78) CDK2FLT3JAK2CCNA2CCNA1
SCHEMBL823862 0.84 JAK2 (0.76) CDK2FLT3JAK2CCNA2CCNA1
SCHEMBL823931 0.83 CDK2 (1.00) CDK2FLT3JAK2CCNA2CCNA1
SCHEMBL823992 0.83 JAK2 (0.78) CDK2FLT3JAK2CCNA2CCNA1
SCHEMBL824009 0.80 JAK2 (0.63) CDK2FLT3JAK2CCNA2CCNA1
SCHEMBL14531120 0.75 FLT3 (0.84) CDK2FLT3JAK2CCNA2CCNA1
SCHEMBL823991 0.74 CDK2 (0.81) CDK2FLT3JAK2CCNA2CCNA1
SCHEMBL824029 0.73 JAK2 (0.66) CDK2FLT3JAK2CCNA2CCNA1
SCHEMBL824008 0.72 JAK2 (1.00) CDK2FLT3JAK2CCNA2CCNA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9133214-B2 Heteroalkyl linked pyrimidine derivatives S*BIO PTE LTD (SG) 2015-09-15 US disclosed
US-9133214-B2 Heteroalkyl linked pyrimidine derivatives S*BIO PTE LTD (SG) 2015-09-15 US disclosed
US-20120142680-A1 HETEROALKYL LINKED PYRIMIDINE DERIVATIVES S*BIO PTE LTD. (SG) 2012-06-07 US disclosed
US-20120142680-A1 HETEROALKYL LINKED PYRIMIDINE DERIVATIVES S*BIO PTE LTD. (SG) 2012-06-07 US disclosed
US-8143255-B2 Heteroalkyl linked pyrimidine derivatives S*BIO PTE LTD. (SG) 2012-03-27 US disclosed
US-8143255-B2 Heteroalkyl linked pyrimidine derivatives S*BIO PTE LTD. (SG) 2012-03-27 US disclosed
US-20090258886-A1 HETEROALKYL LINKED PYRIMIDINE DERIVATIVES S*BIO PTE LTD. (SG) 2009-10-15 US disclosed
US-20090258886-A1 HETEROALKYL LINKED PYRIMIDINE DERIVATIVES S*BIO PTE LTD. (SG) 2009-10-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090258886-A1 HETEROALKYL LINKED PYRIMIDINE DERIVATIVES TK1, TK2, DPYD CDK2 13/4885FLT3 424/4885JAK2 692/4885
US-20120142680-A1 HETEROALKYL LINKED PYRIMIDINE DERIVATIVES TK1, TK2, DPYD CDK2 13/4885FLT3 424/4885JAK2 692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.